AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated highly statistically significant and ...
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 phase III trial showed Enhertu (trastuzumab deruxtecan) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement …